Sustiva/Viracept combo more effective treatment for AIDS relapse
DuPont's Sustiva (efavirenz) and Pfizer's Viracept (nelfinavir),produced by its Agouron Pharmaceuticals subsidiary, are a more effective treatment for AIDS, once the virus has become resistant to other types of therapy, when used in combination than either drug used as a monotherapy over a 48-week period, according to recent research led by Mary Albrecht of Beth Israel Deaconess Medical Center in Boston, USA.
Results of the study, published in the August 8 issue of the New England Journal of Medicine, show that treatment with Sustiva, Viracept and at least one nucleoside analog (zidovudine, didanosine, zalcitabine, stavudine or lamivudine) kept the AIDS virus at bay in 67% of patients, compared to 44% treated with Sustiva plus nucleosides, and 22% of those who received Viracept plus nucleosides.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze